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1. Introduction 
It is now accepted that neuroleptic drugs act by 
blocking dopamine receptors. Direct evidence of such 
* an interaction has been provided by in vitro binding 
studies using [31~]haloperidol [1,2] or dopamine 
agonists [3,4] as ligands. Recently spiperone was 
reported to be a very appropriate ligand, not only for 
in vitro binding assays [5] but especially for in vivo 
binding experiments f6,7] , because of its very high 
affinity and slow dissociation rate (51 . AltIlou~ 
[3HJ spiperone binding was found to be of sero- 
tonergic nature in the frontal cortex [8], there is no 
doubt that it binds to dopaminergic receptors in the 
striatum. 
Preliminary experiments seemed to indicate that 
[3H]spiperot~e binding sites can be solubilized from 
rat striatum [9]. However, the macromolecular com- 
plex thus obtained only revealed a high affinity for 
spiperone but not for other dopamine antagonists. 
We now report the binding characteristics of 
solubilized receptor sites from dog striatum retaining 
the high affinity of membrane preparations. 
2. Materials and methods 
Mongrel dogs were anaesthetized with pentobarbitai 
and their brains were removed. Striata were dissected, 
homogenized in 0.25 M ice-cold sucrose, then frac- 
tionated as in [lo]. The resulting microsomal fraction 
(P) was suspended in 2 vol. ice-cold water and kept at 
-16°C before solubilization. 
2. I. ~~Zub~liz~t~(~~ procedure 
P fraction was treated with digitonin (Serva) 1% 
Elsevier/North-Holland Biomedical Press 
suspended in 4 vol. sucrose 0.25 M containing 10 mM 
sodium phosphate buffer (pH 7.2) and 0.01% NaN,. 
After gently stirring at 0°C for 15 min, the mixture 
was centrifuged at 120 000 X g (ra,) for 60 min. The 
supernat~t was carefully separated from the pellet 
and stored at 0°C. It was then considered ai the 
solubilized preparation (“2 mg protein/ml). 
2.2. Binding procedure 
Soluble material was incubated at 0°C for 16 h 
with ~3H]spiperoIle 2 X 10e9 M (spec. act. 23.6 
Ci.mmol-’ , NEN) and various concentrations of 
unlabelled drugs in 0.5 ml total vol. Stereospecific 
[3H]spiperone binding was defined as the difference 
between the binding in the presence of 2 X 10V7 M 
(-)-butaclamol and 2 X low6 M (+)-butaclamol 151. 
A 0.1 ml aliquot of the incubation mixture was 
layered on a Sephadex G-50 medium column 
(13 X 0.5 cm) and eluted at 2-3°C with sodium 
phosphate buffer 10 mM (pH 7.2) containing 0.01% 
NaN3. Fractions (4 drop) were collected in scintilla- 
tion vials and then counted for the radioactivity. 
2.3. Sucrose graclien t ten trifugation 
Solubilized preparation (0.3 ml) incubated with 
13H]spiperone was layered on a l&30% sucrose 
gradient containing 0.01% NaN3, 10 mM sodium 
phosphate buffer (pH 7.2) and 0.03% digitonin 
(5 ml total vol. in a polyallomer tube). Centrifuga- 
tion was at 2°C in a SW65Ti Spinco rotor (Beckman) 
60 000 rev./min for 7 11. An aliquot of each fraction 
thus obtained was counted for the radioactivity. 
In a second method, a 1 ml aliquot of the 
solub~ized ~naterial was layered on a corltinuous 
sucrose gradient (13 ml total vol.) and centrifuged a 
40 000 rev./min for 16 h in a SW40Ti Spinco rotor. 
t 
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After centrifugation, all the fractions were assayed 
for st~re~~spec~fic binding as above but using a higher 
conceIltration of t3H]spiperone (1O-s M) and (+)- 
butaclamol (10e5 M). 
2.4. Pfvmk aid ~~~~y~~~at~~ assays 
Protein was estimated by the Lowry method [I 11. 
P-Galactosidase (0-G) from Escherichia coli (Aldrich), 
malate dehydrogenase (MDH) from pig heart, lactate 
dellydro~enase (LDH) from rabbit muscle and 
cat&se (CTL) from bovine liver (Boehringer) were 
assayed by different procedures [ 121. Alkaline ~IXOS- 
phatase (ALP) was detected by the hydrolysis of 
~-nitropl~eny~ phosphate [ 131. 
2 S. Muscarinic recep tar assqy 
Fractions of the soluble preparations were incu- 
bated ivith C3H]dexetimide (spec. act. 17 Cimmol~“, 
IRE, Ffeurus) in the nM range with a IOO-foId higher 
concentration of unlabelled levetimide or dexetimide, 
then subil~itt~d to the gel-~ltratjoll procedure [ 121. 
3. Results and discussion 
Figure 1 shows the coIllpet~tion of various neuro- 
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Fig.1. Conlpetition of dopamine antagonists belonging to 
various classes of drugs with [3W]spiperone in solubilized 
dog striatum preparation. 
leptic drugs in the [3H]spiperone binding using a 
solubilized preparation of dog striatum. First (+)- 
bu taclamol (IC 5o = 2.0 X lo-’ M) inhibited the 
binding at a concentration 300-times lower than 
(-)-butaclamol (IC,, = 5.5 X 10e6 M) indicating 
a stereospecific binding ratio colnpar~tble to that 
found in membrane preparations from the rat [5,8] 
and dog (this work). Secondly, the 7 drugs tested 
here which are all dopamine antagonists from dif- 
ferent chemical classes (butyrophcrloIle, diphenyl- 
butylamine, thioxanthene, phenothiazine, procain- 
amide and benzoquinolizine { 141) have K’,. values 
corresponding to those found in membrane prepara- 
tions. which are themselves in agreement with their 
pharmacological and clinical potency f IS]. Further 
evidence of the dopaminergic nature of these soluble 
binding sites was provided by the result that dop- 
amine agonists like (~)-2-(~,.~-dipropylar~lino”5,6- 
dihydroxytctralin (IC,o = 4.8 X 10q7 M) and 
lysuride (Es,, = 1.3 X IO-’ M) also competed at 
very low concentrations. The tetraline derivative was 
demonstrated to be a very specific dopamine agonist 
1161 by displacing spiperone from the binding sites 
in the striatum but not in the frontal cortex [8]. 
In contrast, many other drugs like anticflolii~er~jcs~ 
analgesics. P-blockers, minor tranquilizers and anti- 
serotoninergics were without effect or very weak 
inhibitors of [3H]spiperone binding in the soluble 
preparatioi~. 
As shown in fig.2, by increasing the concentrations 
of E3H]spiperone, the stereospecific binding using 
solubilized preparation was found to be saturable in 
the lo-’ M range, whereas the non-spec~~c biI~din~ 
(measured in the presence of 2 X 10p6 M (+)-buta- 
clamol) increased linearly up to 25 nM. Scatchard 
analysis gave an app k’, W 4.8 nM, a value higher than 
that obtained with the corresponding membrane 
preparation (app k’d = 0.25 n&f). Therefore as found 
for other receptors [ 171 the extraction by detergent 
leads to a decreased affinity, probably by means of 
co~for~lati~r~ changes resulting from the loss of 
environmental lipids. The amount of active receptors 
in solution was -18% when estimated from the 
Scatchard analysis (B,, sofuble = 0.30 pmoI/mg 
protein or 2.7 pmollg tissue and Bmav tnetnbralle = 
0.77 pmol/mg protein or 15.4 pmol/g tissue). 
The [3H]spiperone stereospecific binding was 
reversible (fig.3). Association in the presence of 
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Fig.2. Binding curves at 0°C using a solubilized preparation 
with increasing concentrations of [3H]spiperone: (-•-•-) 
stereospecific binding; (o-o) total binding and (A- -A) non- 
specific binding. The inset shows the Scatchard analysis. 
2 X lo-’ M [3H] spiperone was faster (t,i2 -20 min 
at 5°C) than dissociation in the presence of a lOOO- 
fold excess of unlabelled drug (tr/? = 49 min at 5°C). 
The release of [3H]spiperone showed a first order 
kinetic profile (kdiss = 2.4 X lo4 s-l) and was not 
composed of two straight lines (log C drug-receptor 
complex versus time) as in membrane preparations 
of rat striatum [ 51. 
Figure 4 shows that heat denaturation of dopamine 
receptors was sjrongly increased after digitonin 
extraction as compared to membrane preparations. 
Such a phenomenon was also reported for brain 
muscarinic receptors [ 121. In addition, cerebellum 
extracts did not reveal heat inactivation indicating 
that only non-specific binding sites were detected in 
this brain region. 
The foregoing results clearly show that although 
some differences exist between soluble and mem- 
brane preparations with respect to their kinetics and 
the thermal inactivation, this does not contradict the 
existence of active dopamine receptors in the soluble 
state. 
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Fig.3. Association curve (-o-o-) for the stereospecific 
[3H]spiperone binding in the presence of 2 X 10m9 M 
labelled drug and dissociation curve (o-o) in the presence 
of a lOOO-fold excess of unlabelled drug at 5°C. 
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Fig.4. Comparison of the thermal sensitivity at 30 and 56°C 
for (-) solubilized (S) and (- - - -) membrane (P) prepara- 
tions from dog striatum. 
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F&S(A) Sedimentation profiles of [3H] spiperone in 15-30s sucrose gradient after centrifugation at 260 000 X R (rav) for 7 h with 
a SW65Ti rotor using a solubilized preparation incubated with 2 X 10e9 M of the l&and in the absence (-a--*-) and presence 
(o-o) of 2 X 10e6 M (+)-butaclamol. Control experiment with a membrane preparation (-x -X -) incubated with 2 X 1O-9 M 
[3H]spiperone. 100% represents >2000 dpm/0.2 ml. 5(B) Sedimentation profile of [“Hlspiperone (-a- 0) compared to those of 
[3H]dexetimide (2 X 10m9 M) incubated with a solubilized preparation in the presence of a loo-fold excess unlabelled levetimide 
(m-m) and dexetimide (c-0). 100% represents >1200 dpm/0.2 ml. 5(C) Sedimentation profiles of the stereospecific binding deter- 
mined after centrifugation at 200 000 K (rav) for 16 h with a SW40Ti rotor. t:ractions were incubated with lo-’ M [3H]spiperone 
(A--‘) without and with a lOOO-fold excess of (+)-butaclamol or with lo-’ M [3H]dexetimide (A- -A) in the presence of 10m6 M 
levetimide and dexetimide. loo%, represents for the [‘Hlspiperone distribution -250 dpm/O.l ml and for the [3H]dexetimide 
distribution about 4000 dpm/O.l ml. Marker enzymes: malate dehydrogenase (MDH), lactate dehydrogenase (LDlI), catalase (CTL), 
alkaline phosphatase (ALP) and p-galactosidase (p-G). 
Throughout this work, special attention was paid 
to the criteria of solubilization. One of those consists 
in the sedimentation properties of solubilized binding 
sites through sucrose gradient. 
Figure 5A shows that different sedimentation 
profiles were obtained using either solubilized or 
membrane preparations; indeed the binding sites 
associated with the membranes were only detected in 
the bottom of the tube (fraction 1) while the labelling 
of soluble material appeared as a shoulder, at a 
distance -1/3rd from the top of the tube (fractions 
11-l 5). Such a shoulder profile for the solubilized 
binding sites which was quite reproducible (4 indepen- 
dent runs from different dog striata) disappeared 
when a lOOO-fold excess of (+)-butaclamol was added 
to the incubation mixture (figSA). 
When compared to the sedimentation profile of 
the muscarinic receptor (9 S) which is the same in rat 
[ 121 and dog brain, the solubilized binding sites 
labelled by [3H] spiperone had apparently a lower S 
value. thus indicating a smaller molecular size (fig.5B). 
However, in contrast to [3H] dexetimide which vel-y 
firmly labels muscarinic receptor [ 121, [3H] spiperone 
was found to dissociate from the macromolecular 
complex during the centrifugation; therefore fig.SC 
shows that the real migration of soluble dopamine 
receptors was only detectable when the binding assay 
was performed after the centrifugation run. The 
dopaminergic sites possessed a mean S value which 
was higher than catalase [ 11.3 S) and lower than 
/3-galactosidase (16 S) and may be definitively con- 
sidered as a larger molecular entity than the mus- 
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carinic receptor (-9 S) [12]. Comparison of the 
distribution profiles of both solubilized receptors 
from dog striatum also suggests that dopamine sites 
were markedly more heterogeneous than the mus- 
carinic receptor sites. Alkaline phosphatase (ALP) 
a marker enzyme of the microsomal fraction [ 181 
also extracted from the plasma membrane behaved 
in the gradient as a different entity. Indeed this phos- 
phatase enzyme (mol. wt -190 000 [19]) appeared 
between the muscarinic and dopamine receptors 
approximately where catalase would appear. Such 
results further substantiate the molecular dispersal 
[20] of enzymes and binding sites extracted from 
the same kind of membranes. 
Besides the other criteria of solubilization the non- 
sedimentation of the soluble fraction at 260 000 X g 
(rav) centrifugation for 7 hand the absence of lamellar 
structures [21] in electron microscopic examination 
[22] allow the molecular dispersal of the soluble 
digitonin extract to be assessed. 
The foregoing results demonstrate that dopamine 
receptors from dog striatum solubilized using digitonin. 
The [3H]spiperone binding was found to be very 
stereospecific in competition experiments using 
butaclamol enantiometers. Moreover, these binding 
sites retained their relative affinity for the drugs 
belonging to the principal classes of dopamine anta- 
gonists and also for true dopaminergic agonists like 
lysuride and (*)-2-(N,N-dipropyl)amino-5,6-dihydroxy- 
tetralin. Furthermore, the good correlation of the 
inhibition of [3H]spiperone binding between mem- 
brane and soluble preparation may be extended to a 
pharmacological test, such as the antagonism of 
apomorphine-induced emesis in dog (in preparation). 
The soluble binding sites may associate with and 
dissociate from the ligand and are saturable with 
app K, in accordance with a high affinity. They are 
also very specific for striatum because extraction 
from other brain areas like cerebellum and frontal 
cortex (in preparation) did not allow the detection 
of specific dopaminergic activity. 
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